The basics of CAR T design and challenges in immunotherapy of solid tumors — Ovarian cancer as a model

Abstract

Chimeric antigen receptor T cells are T cells genetically engineered with CAR constructs which mainly contain scFV and TCR zeta chain. With promising development in blood cancers, CAR T trials are also applied in solid cancers. However, the treatment effect in solid cancers is lower than expected. This review summarizes difference of CAR T applications in solid and blood cancers. Future challenges of CAR T cell treatment in solid cancer are also discussed using ovarian cancer as an example.

Keywords

• activation induced cell death (aicd)
• blood cancer
• clinical trial
• chimeric antigen receptor t cells (car t)
• fas/fasl
• mesothelin
• ovarian cancer
• solid cancer